Factors affecting drug concentrations and QT interval during thioridazine therapy

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 555-565

  Thanacoody, R H K ^a   Daly, A K ^a   Reilly, J G ^a   Ferrier, I N ^a   Thomas, S H L ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIDEPRESSANT AGENT; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; BENZODIAZEPINE DERIVATIVE; BUMETANIDE; CAPTOPRIL; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DILTIAZEM; ENALAPRIL; FLUOXETINE; FUROSEMIDE; GLICLAZIDE; HYPNOTIC AGENT; MESORIDAZINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NIFEDIPINE; PAROXETINE; PROPRANOLOL DERIVATIVE; SIMVASTATIN; SULFORIDAZINE; SULFOXIDE; THIORIDAZINE; THYROXINE; TOLBUTAMIDE; UNINDEXED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN VARIANT; QT INTERVAL; QT PROLONGATION; STEADY STATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DOPAMINE ANTAGONISTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEART CONDUCTION SYSTEM; HUMANS; LINEAR MODELS; LONG QT SYNDROME; MALE; MESORIDAZINE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; SMOKING; THIORIDAZINE; VARIATION (GENETICS);

EID: 35248888219     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100195     Document Type: Article

References (36)

1. Thomas, S.H.L. QT interval prolongation and ventricular arrhythmias. Adverse Drug React. Toxicol. Rev. 13, 77-102 (1994).
2. Hartigan-Go, K., Bateman, D.N., Nyberg, G., Martensson, E. & Thomas, S.H.L. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin. Pharmacol. Ther. 60, 543-553 (1996).
3. Kelly, H.Q., Fay, J.E. & Laverty, F.G. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. CMAJ 89, 546-554 (1963).
4. Mehtonen, O.P., Aranko, K., Malkonen, L. & Vapaatalo, H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr. Scand. 84, 58-64 (1991).
5. Ray, W.A., Meredith, S., Thapa, P.B., Meador, K.G., Hall, K. & Murray, K.T. Antipsychotics and the risk of sudden cardiac death. Arch. Gen. Psychiat. 58, 1161-1167 (2001).
6. Reilly, J.G., Ayis, S.A., Ferrier, I.N., Jones, S.J. & Thomas, S.H. Thioridazine and sudden unexplained death in psychiatric inpatients. Br. J. Psychiat. 180, 515-522 (2002).
7. Drolet, B. et al. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J. Pharmacol. Exp. Ther. 288, 1261-1269 (1999).
8. Tie, H., Walker, B.D., Valenzuela, S.M., Breit, S.N. & Campbell, T.J. The heart of psychotropic drug therapy. Lancet 355, 1825 (2001).
9. Lin, G., Hawes, E.M., Mc Kay, G., Korchinski, E.D. & Midha, K.K. Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica 23, 1059-1074 (1993).
10. Von Bahr, C., Movin, G. & Nordin, C. Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin. Pharmacol. Ther. 49, 234-240 (1991).
11. Eap, C.B. et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin. Pharmacol. Ther. 59, 322-331 (1996).
12. Berecz, R., de la Rubia, A., Dorado, P., Fernandez-Salguero, P., Dahl, M.L. & Llerena, A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur. J. Clin. Pharmacol. 59, 45-50 (2003).
13. Carillo, J.A. et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J. Clin. Psychopharmacol. 19, 494-499 (1999).
14. Wojcikowski, J., Maurel, P. & Daniel, W.A. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab. Dispos. 34, 471-476 (2006).
15. Committee on Safety of Medicines. QT interval prolongation with antipsychotics. Current Problems in Pharmacovigilance 27, 4 (2001).
16. Beyeler, C., Daly, A.K., Armstrong, M., Astbury, C., Bird, H.A. & Idle, J.R. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity. J. Rheumatol. 21, 1034-1039 (1994).
17. Cohen, B.M., Lipinski, J.F. & Waternaux, C. A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology 97, 481-488 (1989).
18. Von Bahr, C. et al. Inhibition of desmethylimipramine 2′-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol. 24, 2501-2505 (1985).
19. Baumann, P. et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitryptiline. Ther. Drug Monit. 14, 1-8 (1992).
20. Llerena, A., Berecz, R., de la Rubia, A., Fernandez-Salguero, P. & Dorado, P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. 14, 616-620 (2001).
21. Reilly, J.G., Ayis, S., Ferrier, I.N. & Thomas, S.H.L. QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355, 1048-1052 (2000).
22. Tantcheva-Poor, I., Zaigler, M., Rietbrock, S. & Fuhr, U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 9, 31-144 (1999).
23. Faber, M.S. & Fuhr, U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin. Pharm. Ther. 76, 178-184 (2004).
24. Rasmussen, B.B. et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol. 39, 151-159 (1995).
25. Christensen, M. et al. Low daily 10 mg and 20 mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin. Pharm. Ther. 71, 141-152 (2002).
26. Hale, P.W. Jr & Poklis, A. Thioridazine-5-sulfoxide cardiotoxicity in the isolated, perfused rat heart. Toxicol. Lett. 21, 1-8 (1984).
27. Hine, B., Traficante, L., Sakalis, G. & Gershon, S. Thioridazine and EKG anomalies. Experientia 35, 1631-1632 (1979).
28. Heath, A. Thioridazine toxicity- an experimental cardiovascular study of thioridazine and its major metabolites in overdose. Vet. Hum. Toxicol. 27, 100-105 (1985).
29. Jortani, S.A. & Poklis, A. Determination of thioridazine enantiomers in human serum by sequential achiral and chiral high-performance liquid chromatography. J. Anal. Toxicol. 17, 374-377 (1993).
30. Hale, P.W. Jr & Poklis, A. The biotransformation of thioridazine to thioridazine 5-sulfoxide stereoisomers in phenobarbital induced rats. Eur. J. Drug Metab. Pharmacokinet. 11, 2839 (1986).
31. Salih, I.S.M., Thanacoody, R.H..K., McKay, G.A. & Thomas, S.H.L. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin. Pharmacol. Ther. (submitted).
32. Llerena, A., Berecz, R., la Rubia, A. & Dorado, P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J. Psychopharmacol. 16, 359-362 (2002).
33. Harrigan, E.P. et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 24, 62-69 (2004).
34. Hemeryck, A. & Belpaire, F.M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 3, 13-37 (2002).
35. Daly, A.K., Steen, V.M., Fairbrother, K.S. & Idle, J.R. CYP2D6 multiallelism. Methods Enzymol. 272, 199-210 (1996).
36. Daly, A.K., Monkman, S.C., Smart, J., Steward, A. & Cholerton, S. Analysis of cytochrome P450 polymorphisms. Methods in Molecular Biology vol 107: Cytochrome P450 Protocols (eds. IR Phillips and EA Shephard) Publisher: Humana Press Inc., Totowa, NJ, 405-422.